{'fraction_non_alphanumeric': 0.030110935023771792, 'fraction_numerical': 0.029318541996830427, 'mean_word_length': 5.754010695187166, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 1, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Risperidone treatment of three seriously medically ill children with secondary mood disorders.

Received June 9, 2004; revision received Oct. 16, 2004; accepted Nov. 15, 2004. From the Section of Child and Adolescent Psychiatry, Department of Psychiatry, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis. Address correspondence and reprint requests to Dr. Meighen, James Whitcomb Riley Hospital for Children, 702 Barnhill Dr., Rm. 4300, Indianapolis, IN 46202-5200; kmeighen@iupui.edu (e-mail). Copyright 2005 The Academy of Psychosomatic Medicine. Atypical antipsychotics are increasingly used in child and adolescent populations for a variety of psychiatric disorders. Compared to conventional antipsychotics, their appeal is at least twofold: tolerability and unique neurotransmitter receptor affinities that translate into applicability beyond schizophrenia and other psychotic disorders. We present three cases from a child and adolescent consultation-liaison psychiatry service where risperidone was used to treat significant mood disorders secondary to serious medical conditions. These cases represent novel uses of risperidone because of the very young ages of the children and the diagnoses being treated.